Search

Your search keyword '"Noordzij, W"' showing total 194 results
Start Over Author "Noordzij, W"

Refine your results

194 results on '"Noordzij, W"'

7. PSMA PET/CT based clinical target volume delineation guideline for post-prostatectomy salvage radiation therapy: the PERYTON-Guideline

Author

Staal, F.H.E., primary, Janssen, J., additional, Oprea-Lager, D.E, additional, Engelen, A.M, additional, van Limbergen, E.J, additional, Smeenk, R.J, additional, de Jong, M.A.A, additional, Budiharto, T.C.G, additional, Jacobs, I., additional, Haverkort, M.A.D, additional, Brouwer, C.L, additional, Siang, K. Ng Wei, additional, Langendijk, J.A, additional, Verzijlbergen, J.F, additional, de Jong, I.J, additional, Noordzij, W., additional, and Aluwini, S., additional

Published
2023
Full Text
View/download PDF

8. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting

Author

Mehra, N., Kloots, I., Vlaming, M., Aluwini, S., Dewulf, E., Oprea-Lager, D.E., Poel, H. van der, Stoevelaar, H., Yakar, D., Bangma, Chris H., Bekers, E., Bergh, Roderick van den, Bergman, A.M., Berkmortel, F. van den, Boudewijns, S, Dinjens, W.N., Futterer, J.J., Hulle, T. van der, Jenster, G., Kroeze, L., Kruchten, M. van, Leenders, G. van, Leeuwen, P.J. van, Leng, W.W.J. de, Moorselaar, R.J.A. van, Noordzij, W., Oldenburg, R.A., Oort, I.M. van, Oving, I., Schalken, J.A., Schoots, I.G., Schuuring, E., Smeenk, R.J., Vanneste, B.G.L., Vegt, E, Vis, Andre N., Vries, K. de, Willemse, P.M., Wondergem, M., Ausems, M., Mehra, N., Kloots, I., Vlaming, M., Aluwini, S., Dewulf, E., Oprea-Lager, D.E., Poel, H. van der, Stoevelaar, H., Yakar, D., Bangma, Chris H., Bekers, E., Bergh, Roderick van den, Bergman, A.M., Berkmortel, F. van den, Boudewijns, S, Dinjens, W.N., Futterer, J.J., Hulle, T. van der, Jenster, G., Kroeze, L., Kruchten, M. van, Leenders, G. van, Leeuwen, P.J. van, Leng, W.W.J. de, Moorselaar, R.J.A. van, Noordzij, W., Oldenburg, R.A., Oort, I.M. van, Oving, I., Schalken, J.A., Schoots, I.G., Schuuring, E., Smeenk, R.J., Vanneste, B.G.L., Vegt, E, Vis, Andre N., Vries, K. de, Willemse, P.M., Wondergem, M., and Ausems, M.

Abstract

Item does not contain fulltext, BACKGROUND: Germline and tumour genetic testing in prostate cancer (PCa) is becoming more broadly accepted, but testing indications and clinical consequences for carriers in each disease stage are not yet well defined. OBJECTIVE: To determine the consensus of a Dutch multidisciplinary expert panel on the indication and application of germline and tumour genetic testing in PCa. DESIGN SETTING AND PARTICIPANTS: The panel consisted of 39 specialists involved in PCa management. We used a modified Delphi method consisting of two voting rounds and a virtual consensus meeting. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was reached if ≥75% of the panellists chose the same option. Appropriateness was assessed by the RAND/UCLA appropriateness method. RESULTS AND LIMITATIONS: Of the multiple-choice questions, 44% reached consensus. For men without PCa having a relevant family history (familial PCa/BRCA-related hereditary cancer), follow-up by prostate-specific antigen was considered appropriate. For patients with low-risk localised PCa and a family history of PCa, active surveillance was considered appropriate, except in case of the patient being a BRCA2 germline pathogenic variant carrier. Germline and tumour genetic testing should not be done for nonmetastatic hormone-sensitive PCa in the absence of a relevant family history of cancer. Tumour genetic testing was deemed most appropriate for the identification of actionable variants, with uncertainty for germline testing. For tumour genetic testing in metastatic castration-resistant PCa, consensus was not reached for the timing and panel composition. The principal limitations are as follows: (1) a number of topics discussed lack scientific evidence, and therefore the recommendations are partly opinion based, and (2) there was a small number of experts per discipline. CONCLUSIONS: The outcomes of this Dutch consensus meeting may provide further guidance on genetic counselling and molecular testing related to PCa.

Published
2023

9. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA.

Author

Veltmaat, N., Zhong, Y., Jesus, F.M. de, Tan, G.W., Bult, J.A.A., Terpstra, M.M., Mutsaers, P.G.N.J., Stevens, W.B.C., Mous, R., Vermaat, J.S.P., Chamuleau, M.E.D., Noordzij, W., Verschuuren, E.A.M., Kok, K., Kluiver, J.L., Diepstra, A., Plattel, W.J., Berg, A. van den, Nijland, M., Veltmaat, N., Zhong, Y., Jesus, F.M. de, Tan, G.W., Bult, J.A.A., Terpstra, M.M., Mutsaers, P.G.N.J., Stevens, W.B.C., Mous, R., Vermaat, J.S.P., Chamuleau, M.E.D., Noordzij, W., Verschuuren, E.A.M., Kok, K., Kluiver, J.L., Diepstra, A., Plattel, W.J., Berg, A. van den, and Nijland, M.

Abstract

Contains fulltext : 296504.pdf (Publisher’s version ) (Open Access), Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic PTLD after solid organ transplantation in this multi-center observational cohort study. We used low-coverage whole genome sequencing (lcWGS) to detect copy number variations (CNVs) and targeted next-generation sequencing (NGS) to identify Epstein-Barr virus (EBV) DNA load and somatic single nucleotide variants (SNVs) in cfDNA from plasma. Seven out of seventeen (41%) patients had EBV-positive tumors, and 13/17 (76%) had stage IV disease. Nine out of seventeen (56%) patients showed CNVs in cfDNA, with more CNVs in EBV-negative cases. Recurrent gains were detected for 3q, 11q, and 18q. Recurrent losses were observed at 6q. The fraction of EBV reads in cfDNA from EBV-positive patients was 3-log higher compared to controls and EBV-negative patients. 289 SNVs were identified, with a median of 19 per sample. SNV burden correlated significantly with lactate dehydrogenase levels. Similar SNV burdens were observed in EBV-negative and EBV-positive PTLD. The most commonly mutated genes were TP53 and KMT2D (41%), followed by SPEN, TET2 (35%), and ARID1A, IGLL5, and PIM1 (29%), indicating DNA damage response, epigenetic regulation, and B-cell signaling/NFkB pathways as drivers of PTLD. Overall, CNVs were more prevalent in EBV-negative lymphoma, while no difference was observed in the number of SNVs. Our data indicated the potential of analyzing cfDNA as a tool for PTLD screening and response monitoring.

Published
2023

10. [15O]H2O PET: Potential or Essential for Molecular Imaging?

Author

Slart, R, Martinez-Lucio, T, Boersma, H, Borra, R, Cornelissen, B, Dierckx, R, Dobrolinska, M, Doorduin, J, Erba, P, Glaudemans, A, Giacobbo, B, Luurtsema, G, Noordzij, W, van Sluis, J, Tsoumpas, C, Lammertsma, A, Slart, Riemer H J A, Martinez-Lucio, T Samara, Boersma, Hendrikus H, Borra, Ronald H, Cornelissen, Bart, Dierckx, Rudi A J O, Dobrolinska, Magdalena, Doorduin, Janine, Erba, Paola A, Glaudemans, Andor W J M, Giacobbo, Bruno Lima, Luurtsema, Gert, Noordzij, Walter, van Sluis, Joyce, Tsoumpas, Charalampos, Lammertsma, Adriaan A, Slart, R, Martinez-Lucio, T, Boersma, H, Borra, R, Cornelissen, B, Dierckx, R, Dobrolinska, M, Doorduin, J, Erba, P, Glaudemans, A, Giacobbo, B, Luurtsema, G, Noordzij, W, van Sluis, J, Tsoumpas, C, Lammertsma, A, Slart, Riemer H J A, Martinez-Lucio, T Samara, Boersma, Hendrikus H, Borra, Ronald H, Cornelissen, Bart, Dierckx, Rudi A J O, Dobrolinska, Magdalena, Doorduin, Janine, Erba, Paola A, Glaudemans, Andor W J M, Giacobbo, Bruno Lima, Luurtsema, Gert, Noordzij, Walter, van Sluis, Joyce, Tsoumpas, Charalampos, and Lammertsma, Adriaan A

Abstract

Imaging water pathways in the human body provides an excellent way of measuring accurately the blood flow directed to different organs. This makes it a powerful diagnostic tool for a wide range of diseases that are related to perfusion and oxygenation. Although water PET has a long history, its true potential has not made it into regular clinical practice. The article highlights the potential of water PET in molecular imaging and suggests its prospective role in becoming an essential tool for the 21st century precision medicine in different domains ranging from preclinical to clinical research and practice. The recent technical advances in high-sensitivity PET imaging can play a key accelerating role in empowering this technique, though there are still several challenges to overcome.

Published
2023

11. A dual-tracer approach using [11C]CH and [18F]FDG in HCC clinical decision making

Author

Veenstra, E, Ruiter, S, de Haas, R, de Jong, K, Erba, P, Dierckx, R, Noordzij, W, Veenstra, Emile B, Ruiter, Simeon J S, de Haas, Robbert J, de Jong, Koert P, Erba, Paola A, Dierckx, Rudi A J O, Noordzij, Walter, Veenstra, E, Ruiter, S, de Haas, R, de Jong, K, Erba, P, Dierckx, R, Noordzij, W, Veenstra, Emile B, Ruiter, Simeon J S, de Haas, Robbert J, de Jong, Koert P, Erba, Paola A, Dierckx, Rudi A J O, and Noordzij, Walter

Abstract

Background: Early detection of recurrent or progressive HCC remains the strongest prognostic factor for survival. Dual tracer PET/CT imaging with [11C]CH and [18F]FDG can further increase detection rates as both tracers entail different metabolic pathways involved in HCC development. We investigated dual-tracer PET/CT in clinical decision making in patients suspected of recurrent or progressive HCC. All HCC patients who underwent both [11C]CH and [18F]FDG PET/CT in our institute from February 2018 to December 2021 were included. Both tracer PET/CT were within 4 weeks of each other with at least 6-month follow-up. Patients underwent dual tracer PET/CT because of unexplained and suspicious CT/MRI or sudden rise of serum tumour markers. A detected lesion was considered critical when the finding had prognostic consequences leading to treatment changes. Results: Nineteen patients who underwent [11C]CH and [18F]FDG PET/CT were included of which all but six patients were previously treated for HCC. Dual-tracer critical finding detection rate was 95%, with [18F]FDG 68%, and [11C]CH 84%. Intrahepatic HCC recurrence finding rate was 65% for both tracers. [18F]FDG found more ablation site recurrences (4/5) compared to [11C]CH (2/5). Only [11C]CH found two needle tract metastases. Both tracers found 75% of the positive lymph nodes. Two new primary tumours were found, one by [18F]FDG and both by [11C]CH. Conclusions: Our study favours a dual-tracer approach in HCC staging in high-risk patients or when conventional imaging is non-conclusive.

Published
2023

16. Dose response modelling of secretory cell loss in salivary glands using PSMA PET

Author

MS Radiotherapie, MS Radiologie, Cancer, Mohan, V, Bruin, N M, Steenbakkers, R J H M, Noordzij, W, Terhaard, C H J, de Keizer, B, Al-Mamgani, A, van de Kamer, J B, Sonke, J-J, Vogel, W V, MS Radiotherapie, MS Radiologie, Cancer, Mohan, V, Bruin, N M, Steenbakkers, R J H M, Noordzij, W, Terhaard, C H J, de Keizer, B, Al-Mamgani, A, van de Kamer, J B, Sonke, J-J, and Vogel, W V

Published
2022

17. Long axial field of view PET scanners: a road map to implementation and new possibilities

Author

Slart, RHJA, Tsoumpas, C, Glaudemans, AWJM, Noordzij, W, Willemsen, ATM, Borra, RJH, Dierckx, RAJO, and Lammertsma, AA

Abstract

In this contribution, several opportunities and challenges for long axial field of view (LAFOV) PET are described. It is an anthology in which the main issues have been highlighted. A consolidated overview of the camera system implementation, business and financial plan, opportunities and challenges is provided. What the nuclear medicine and molecular imaging community can expect from these new PET/CT scanners is the delivery of more comprehensive information to the clinicians for advancing diagnosis, therapy evaluation and clinical research.

Published
2021

20. Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [F]FDG PET/CT

Author

Montes de Jesus, Felipe, Vergote, V, Noordzij, W, Dierickx, D, Dierckx, R A J O, Diepstra, A, Tousseyn, T, Gheysens, O, Kwee, T C, Deroose, C M, Glaudemans, A W J M, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine nucléaire, and UCL - (SLuc) Centre du cancer

Subjects
surgical procedures, operative, 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography, hemic and lymphatic diseases, standardized uptake value, semi-quantification, post-transplant lymphoproliferative disorder, FDG-PET/CT
Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a complication of organ transplantation classified according to the WHO as nondestructive, polymorphic, monomorphic, and classic Hodgkin Lymphoma subtypes. In this retrospective study, we investigated the potential of semi-quantitative 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG) PET/computed tomography (CT)-based parameters to differentiate between the PTLD morphological subtypes. 96 patients with histopathologically confirmed PTLD and baseline [F]FDG PET/CT between 2009 and 2019 were included. Extracted semi-quantitative measurements included: Maximum, peak, and mean standardized uptake value (SUV, SUV, and SUV). Median SUVs were highest for monomorphic PTLD followed by polymorphic and nondestructive subtypes. The median SUV at the biopsy site was significantly higher in monomorphic PTLD (17.8, interquartile range (IQR):16) than in polymorphic subtypes (9.8, IQR:13.4) and nondestructive (4.1, IQR:6.1) ( = 0.04 and ≤ 0.01, respectively). An SUV ≥ 24.8 was always indicative of a monomorphic PTLD in our dataset. Nevertheless, there was a considerable overlap in SUV across the different morphologies. The median SUV at the biopsy site was significantly higher in monomorphic PTLD than polymorphic and nondestructive subtypes. However, due to significant SUV overlap across the different subtypes, these values may only serve as an indication of PTLD morphology, and SUV-based parameters cannot replace histopathological classification.

Published
2021

21. Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial

Author

Privé, B.M., Janssen, M.J.R., Oort, I.M. van, Muselaers, C.H.J., Jonker, M.A., Gemert, W.A. van, Groot, M. de, Westdorp, H., Mehra, N., Verzijlbergen, J.F., Scheenen, T.W.J., Zámecnik, P., Barentsz, J.O., Gotthardt, M., Noordzij, W., Vogel, W.V., Bergman, A.M., Poel, H.G. van der, Vis, Andre N., Oprea-Lager, D.E., Gerritsen, W.R., Witjes, J.A., Nagarajah, J., Privé, B.M., Janssen, M.J.R., Oort, I.M. van, Muselaers, C.H.J., Jonker, M.A., Gemert, W.A. van, Groot, M. de, Westdorp, H., Mehra, N., Verzijlbergen, J.F., Scheenen, T.W.J., Zámecnik, P., Barentsz, J.O., Gotthardt, M., Noordzij, W., Vogel, W.V., Bergman, A.M., Poel, H.G. van der, Vis, Andre N., Oprea-Lager, D.E., Gerritsen, W.R., Witjes, J.A., and Nagarajah, J.

Abstract

Contains fulltext : 244316.pdf (Publisher’s version ) (Open Access), BACKGROUND: The BULLSEYE trial is a multicenter, open-label, randomized controlled trial to test the hypothesis if (177)Lu-PSMA is an effective treatment in oligometastatic hormone-sensitive prostate cancer (oHSPC) to prolong the progression-free survival (PFS) and postpone the need for androgen deprivation therapy (ADT). The original study protocol was published in 2020. Here, we report amendments that have been made to the study protocol since the commencement of the trial. CHANGES IN METHODS AND MATERIALS: Two important changes were made to the original protocol: (1) the study will now use (177)Lu-PSMA-617 instead of (177)Lu-PSMA-I&T and (2) responding patients with residual disease on (18)F-PSMA PET after the first two cycles are eligible to receive additional two cycles of 7.4 GBq (177)Lu-PSMA in weeks 12 and 18, summing up to a maximum of 4 cycles if indicated. Therefore, patients receiving (177)Lu-PSMA-617 will also receive an interim (18)F-PSMA PET scan in week 4 after cycle 2. The title of this study was modified to; "Lutetium-177-PSMA in Oligo-metastatic Hormone Sensitive Prostate Cancer" and is now partly supported by Advanced Accelerator Applications, a Novartis Company. CONCLUSIONS: We present an update of the original study protocol prior to the completion of the study. Treatment arm patients that were included and received (177)Lu-PSMA-I&T under the previous protocol will be replaced. TRIAL REGISTRATION: ClinicalTrials.gov NCT04443062 . First posted: June 23, 2020.

Published
2021

22. Prognostic superiority of International Prognostic Index over [F]FDG PET/CT volumetric parameters in post-transplant lymphoproliferative disorder.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de médecine nucléaire, Montes de Jesus, F, Dierickx, D, Vergote, V, Noordzij, W, Dierckx, R A J O, Deroose, C M, Glaudemans, A W J M, Gheysens, O, Kwee, T C, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de médecine nucléaire, Montes de Jesus, F, Dierickx, D, Vergote, V, Noordzij, W, Dierckx, R A J O, Deroose, C M, Glaudemans, A W J M, Gheysens, O, and Kwee, T C

Abstract

Post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of hematological malignancies occurring after solid organ and hematopoietic stem cell transplantation. [F]FDG PET/CT is routinely performed at PTLD diagnosis, allowing for both staging of the disease and quantification of volumetric parameters, such as whole-body metabolic tumor volume (MTV) and total lesion glycolysis (TLG). In this retrospective study, we aimed to determine the prognostic value of MTV and TLG in PTLD patients, together with other variables of interest, such as the International Prognostic Index (IPI), organ transplant type, EBV tumor status, time after transplant, albumin levels and PTLD morphology. A total of 88 patients were included. The 1-, 3-, 5- year overall survival rates were 67%, 58% and 43% respectively. Multivariable analysis indicated that a high IPI (HR: 1.56, 95% CI: 1.13-2.16) and an EBV-negative tumor (HR: 2.71, 95% CI: 1.38-5.32) were associated with poor overall survival. Patients with a kidney transplant had a longer overall survival than any other organ recipients (HR: 0.38 95% CI: 0.16-0.89). IPI was found to be the best predicting parameter of overall survival in our cohort. Whole-body MTV, TLG, time after transplant, hypoalbuminemia and PTLD morphology were not associated with overall survival. [F]FDG PET/CT whole-body volumetric quantitative parameters were not predictive of overall survival in PTLD. In our cohort, high IPI and an EBV-negative tumor were found to predictors of worse overall survival while kidney transplant patients had a longer overall survival compared to other organ transplant recipients.

Published
2021

23. Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [F]FDG PET/CT.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Centre du cancer, Montes de Jesus, Felipe, Vergote, V, Noordzij, W, Dierickx, D, Dierckx, R A J O, Diepstra, A, Tousseyn, T, Gheysens, O, Kwee, T C, Deroose, C M, Glaudemans, A W J M, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Centre du cancer, Montes de Jesus, Felipe, Vergote, V, Noordzij, W, Dierickx, D, Dierckx, R A J O, Diepstra, A, Tousseyn, T, Gheysens, O, Kwee, T C, Deroose, C M, and Glaudemans, A W J M

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a complication of organ transplantation classified according to the WHO as nondestructive, polymorphic, monomorphic, and classic Hodgkin Lymphoma subtypes. In this retrospective study, we investigated the potential of semi-quantitative 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG) PET/computed tomography (CT)-based parameters to differentiate between the PTLD morphological subtypes. 96 patients with histopathologically confirmed PTLD and baseline [F]FDG PET/CT between 2009 and 2019 were included. Extracted semi-quantitative measurements included: Maximum, peak, and mean standardized uptake value (SUV, SUV, and SUV). Median SUVs were highest for monomorphic PTLD followed by polymorphic and nondestructive subtypes. The median SUV at the biopsy site was significantly higher in monomorphic PTLD (17.8, interquartile range (IQR):16) than in polymorphic subtypes (9.8, IQR:13.4) and nondestructive (4.1, IQR:6.1) ( = 0.04 and ≤ 0.01, respectively). An SUV ≥ 24.8 was always indicative of a monomorphic PTLD in our dataset. Nevertheless, there was a considerable overlap in SUV across the different morphologies. The median SUV at the biopsy site was significantly higher in monomorphic PTLD than polymorphic and nondestructive subtypes. However, due to significant SUV overlap across the different subtypes, these values may only serve as an indication of PTLD morphology, and SUV-based parameters cannot replace histopathological classification.

Published
2021

24. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Author

Aluwini, S.S., Mehra, N., Lolkema, M.P., Oprea-Lager, D.E., Yakar, D., Stoevelaar, H., Poel, H.G. van der, Busstra, M., Jong, I.J. de, Reijke, T. de, Vries, K. de, Heijmink, S., Jenster, G., Klaver, S., Kneppers, J., Lavalaye, J., Leyten, G., Moonen, L., Nagaraj, J., Noordzij, W., Osanto, S., Oving, I., Schaake, E., Scheenen, T.W.J., Schoots, I., Sedelaar, M., Somford, D.M., Berkmortel, F.W. van den, Hulle, T. van der, Voort van Zyp, J.R.N. van der, Leeuwen, P. van, Moorselaar, J. van, Oort, I.M. van, Vogel, W., Westgeest, H., Aluwini, S.S., Mehra, N., Lolkema, M.P., Oprea-Lager, D.E., Yakar, D., Stoevelaar, H., Poel, H.G. van der, Busstra, M., Jong, I.J. de, Reijke, T. de, Vries, K. de, Heijmink, S., Jenster, G., Klaver, S., Kneppers, J., Lavalaye, J., Leyten, G., Moonen, L., Nagaraj, J., Noordzij, W., Osanto, S., Oving, I., Schaake, E., Scheenen, T.W.J., Schoots, I., Sedelaar, M., Somford, D.M., Berkmortel, F.W. van den, Hulle, T. van der, Voort van Zyp, J.R.N. van der, Leeuwen, P. van, Moorselaar, J. van, Oort, I.M. van, Vogel, W., and Westgeest, H.

Abstract

Item does not contain fulltext, BACKGROUND: Oligometastatic prostate cancer (OMPC) is a heterogeneous disease state that is imperfectly understood, and its clinical implications are unclear. OBJECTIVE: To determine the consensus of a Dutch multidisciplinary expert panel on biological aspects, treatment goals, and management of OMPC in daily clinical practice. DESIGN, SETTING, AND PARTICIPANTS: The study comprised a modified Delphi method including an explorative survey with various statements and questions, followed by a consensus meeting to discuss and determine the agreement with revised statements and related items. The panel consisted of 34 Dutch representatives from urology, medical and radiation oncology, radiology, nuclear medicine, and basic research. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Agreement was determined with statements (five-point scale). Consensus was defined as >/=75% panel agreement with a statement. RESULTS AND LIMITATIONS: Consensus existed for 56% of statements. The panel agreed that OMPC comprises a limited metastatic spread in the hormone-sensitive setting, in both the synchronous and the metachronous presentation. Limited metastatic spread was believed to involve three to five metastases and a maximum of two organs. Prostate-specific membrane antigen positron emission tomography/computed tomography scan was currently perceived as the most accurate diagnostic imaging modality. Although there was a consensus that targeted treatment of all metastases in OMPC will delay further dissemination of the disease, opinions on specific treatment regimens were divided. Panel outcomes were limited by the lack of scientific evidence on OMPC. CONCLUSIONS: A multidisciplinary panel reached a consensus that OMPC is a specific disease state requiring a tailored treatment approach. OMPC registries and clinical studies should focus on both the biology and the clinical parameters in relation to optimal treatment strategies in synchronous and metachronous OMPC. PATIENT SUMMARY: A grou

Published
2020

25. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

Author

Privé, B.M., Janssen, M.J.R., Oort, I.M. van, Muselaers, C.H.J., Jonker, M.A., Groot, M. de, Mehra, N., Verzijlbergen, J.F., Scheenen, T.W.J., Zamecnik, P., Barentsz, J.O., Gotthardt, M., Noordzij, W., Vogel, W.V., Bergman, A.M., Poel, H.G. van der, Vis, Andre N., Oprea-Lager, D.E., Gerritsen, W.R., Witjes, J.A., Nagarajah, J., Privé, B.M., Janssen, M.J.R., Oort, I.M. van, Muselaers, C.H.J., Jonker, M.A., Groot, M. de, Mehra, N., Verzijlbergen, J.F., Scheenen, T.W.J., Zamecnik, P., Barentsz, J.O., Gotthardt, M., Noordzij, W., Vogel, W.V., Bergman, A.M., Poel, H.G. van der, Vis, Andre N., Oprea-Lager, D.E., Gerritsen, W.R., Witjes, J.A., and Nagarajah, J.

Abstract

Contains fulltext : 225057.pdf (publisher's version ) (Open Access), BACKGROUND: In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone sensitive prostate cancer (oHSPC). However, many patients do not qualify for these treatments due to prior interventions or tumor location. Such oligometastatic patients could benefit from radioligand therapy (RLT) with (177)Lu-PSMA; a novel tumor targeting therapy for end-stage metastatic castration-resistant prostate cancer (mCRPC). Especially because RLT could be more effective in low volume disease, such as the oligometastatic status, due to high uptake of radioligands in smaller lesions. To test the hypothesis that (177)Lu-PSMA is an effective treatment in oHSPC to prolong PFS and postpone the need for androgen deprivation therapy (ADT), we initiated a multicenter randomized clinical trial. This is globally, the first prospective study using (177)Lu-PSMA-I&T in a randomized multicenter setting. METHODS & DESIGN: This study compares (177)Lu-PSMA-I&T MDT to the current standard of care (SOC); deferred ADT. Fifty-eight patients with oHSPC (≤5 metastases on PSMA PET) and high PSMA uptake (SUVmax > 15, partial volume corrected) on (18)F-PSMA PET after prior surgery and/or EBRT and a PSA doubling time of < 6 months, will be randomized in a 1:1 ratio. The patients randomized to the interventional arm will be eligible for two cycles of 7.4GBq (177)Lu-PSMA-I&T at a 6-week interval. After both cycles, patients are monitored every 3 weeks (including adverse events, QoL- and xerostomia questionnaires and laboratory testing) at the outpatient clinic. Twenty-four weeks after cycle two an end of study evaluation is planned together with another (18)F-PSMA PET and (whole body) MRI. Patients in the SOC arm are eligible to receive (177)Lu-PSMA-I&T after meeting the primary study objective, which is the fraction of patients who show

Published
2020

26. Machine learning in the differentiation of follicular lymphoma from diffuse large B-cell lymphoma with radiomic [18F]FDG PET/CT features.

Author

de Jesus, F. Montes, Yin, Y., Mantzorou-Kyriaki, E., Kahle, X. U., de Haas, R. J., Yakar, D., Glaudemans, A. W. J. M., Noordzij, W., Kwee, T. C., and Nijland, M.

Subjects
LYMPHOMA diagnosis, CELL differentiation, MACHINE learning, B cell lymphoma, CYTOCHEMISTRY, RADIOPHARMACEUTICALS, POSITRON emission tomography, DESCRIPTIVE statistics, DEOXY sugars, COMPUTED tomography, LOGISTIC regression analysis, SENSITIVITY & specificity (Statistics), ALGORITHMS
Abstract

Background: One of the challenges in the management of patients with follicular lymphoma (FL) is the identification of individuals with histological transformation, most commonly into diffuse large B-cell lymphoma (DLBCL). [18F]FDG-PET/CT is used for staging of patients with lymphoma, but visual interpretation cannot reliably discern FL from DLBCL. This study evaluated whether radiomic features extracted from clinical baseline [18F]FDG PET/CT and analyzed by machine learning algorithms may help discriminate FL from DLBCL. Materials and methods: Patients were selected based on confirmed histopathological diagnosis of primary FL (n=44) or DLBCL (n=76) and available [18F]FDG PET/CT with EARL reconstruction parameters within 6 months of diagnosis. Radiomic features were extracted from the volume of interest on co-registered [18F]FDG PET and CT images. Analysis of selected radiomic features was performed with machine learning classifiers based on logistic regression and tree-based ensemble classifiers (AdaBoosting, Gradient Boosting, and XG Boosting). The performance of radiomic features was compared with a SUVmax-based logistic regression model. Results: From the segmented lesions, 121 FL and 227 DLBCL lesions were included for radiomic feature extraction. In total, 79 radiomic features were extracted from the SUVmap, 51 from CT, and 6 shape features. Machine learning classifier Gradient Boosting achieved the best discrimination performance using 136 radiomic features (AUC of 0.86 and accuracy of 80%). SUVmax-based logistic regression model achieved an AUC of 0.79 and an accuracy of 70%. Gradient Boosting classifier had a significantly greater AUC and accuracy compared to the SUVmax-based logistic regression (p≤0.01). Conclusion: Machine learning analysis of radiomic features may be of diagnostic value for discriminating FL from DLBCL tumor lesions, beyond that of the SUVmax alone. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Characterization of post-transplant lymphoproliferative disorder with semi-quantitative FDG-PET/CT

Author

Montes De Jesus, F., Noordzij, W., Kahle, X., Nijland, M., Verschuuren, E., Dierckx, R., Van Der Meerten, T., Van Der Bij, W., Huls, G., Kwee, T., Glaudemans, A., Molecular Neuroscience and Ageing Research (MOLAR), Stem Cell Aging Leukemia and Lymphoma (SALL), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Translational Immunology Groningen (TRIGR), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Groningen Institute for Organ Transplantation (GIOT)

Subjects
cancer patient, clinical article, posttransplant lymphoproliferative disease, conference abstract, quantitative analysis, software, adult, human cell, practice guideline, immunosuppressive treatment, lymph node, PET-CT scanner, surgical procedures, operative, classical Hodgkin lymphoma, female, peak standardized uptake value, male, hemic and lymphatic diseases, histopathology, positron emission tomography-computed tomography, controlled study, maximum standardized uptake value, human, mean standardized uptake value
Abstract

Aim/Introduction: One of the most dire complications of hematopoietic stem cell (HSCT) and solid organ transplantation (SOT) is the development of post-transplant lymphoproliferative disorder (PTLD). PTLD compromises a broad spectrum of disorders classified by the 2017 World Health Organization (WHO) in non-destructive, polymorphic, monomorphic and classic Hodgkin lymphoma. Distinct morphologies are associated with a more favorable clinical course and better response to initial treatment. Reduction of immunosuppression, commonly used as first-line treatment, has been associated with higher response rates in non-destructive and polymorphic PTLD, while a more aggressive therapy is advised for monomorphic PTLD. Biopsy is the reference standard for PTLD diagnosis and classification, but may not always be safely possible. Therefore, there is a need for non-invasive imaging-based tools. Materials and Methods: All patients with histopathologically proven PTLD at the UMC Groningen were included in this study between January 2010 to March 2019. FDG-PET/CT scans were performed on a Siemens Biograph mCT camera, according to EANM procedure guidelines for tumor imaging and reconstruction parameters compliant with EARL recommendations. Semi-quantitative measurements (SUVmax, SUVpeak and SUVmean) were performed using dedicated Hermes Hybrid 3D software with the ?Tumor Finder? application. Semi-quantitative measurements were obtained from the biopsy site or in cases in which a biopsy was performed before the scan from the nearest lymph node in the same lymph node region Results: In total 41 patients were included. From those, 27 were monomorphic PTLD and 14 were ?other PTLD morphologies?, including non-destructive (n=4), polymorphic (n=9) and Hodgkin-like PTLD (n=1). Median SUVmax, SUVpeak, SUVmean values were statistically significantly higher in monomorphic PTLD than in ?other PTLD morphologies (p

Published
2019

30. Image quality and activity optimization in oncological 18F-FDG PET using the digital Biograph Vision PET/CT

Author

Sluis van, Joyce, Boellaard, Ronald, Dierckx, Rudi A. J. O., Stormezand, Gilles N., Glaudemans, Andor W. J. M., and Noordzij, W.

Subjects
PET/CT, SiPM, mental disorders, Biograph Vision, Image quality, psychological phenomena and processes, Image analysis
Abstract

Qualitative image analysis scores (based on a5-point Likert scale)of PET/CT images obtained at 180 seconds per bed position versus 60 seconds per bed position.

Published
2019
Full Text
View/download PDF

31. Optimization of 11C-choline positron emission tomography protocol for localization of parathyroid adenomas in patients with primary hyperparathyroidism

Author

Noltes, M.E., Kruijf, S., Noordzij, W., Telenga, E., Vállez García, D., Trofmiuk-Müldner, M., Opalínska, M., Hubalewska-Dydejczyk, A., Luurtsema, G., Dierckx, R.A.J.O., El Moumni, M., Boellaard, R., Brouwers, A.H., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Molecular Neuroscience and Ageing Research (MOLAR), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Subjects
clinical article, conference abstract, adult, retrospective study, tracer, choline uptake, human tissue, female, injection, male, parathyroid adenoma, choline, radioactivity, randomized controlled trial, positron emission tomography-computed tomography, controlled study, human, primary hyperparathyroidism, mean standardized uptake value, statistical significance, thyroid gland tissue
Abstract

Purpose: To evaluate the optimal tracer uptake time, the minimally amount of radioactivity and the inter-observer agree-ment for 11C-choline positron emission tomography/computed tomography (PET/CT) in patients with primary hyperparathy-roidism (pHPT). Subjects & methods: Twenty-one patients with clinically suspected pHPT were retrospectively studied after injection of mean 6.3 ± 1.2 MBq/kg. PET list mode data of the first nine patients, scanned for up to max 60 min, were reconstructed in 10 min frames mimicking varying 11C-choline uptake times from 10 to 60 min postinjection (p.i.) to assess optimal tracer uptake time. Parathyroid adenoma (PTA) to background contrast ratios were calculated, using standardized uptake values (SUVs), and compared. The first time frame in which there were no significant differences compared to later time frames, was considered the optimal uptake time. Also, data was reconstructed with varying durations (1, 2.5 and 5 min) at 20-30 min p.i. (established optimal uptake time), mimicking less administered radioactivity. To establish the minimal radioactivity administered, the variability of SUVs for PTA and thyroid tissue, normalized to 10 min time frame level of the established optimal uptake time (since the individual measurements of SUV per patient varied considerably), was analysed. Furthermore, four observers were asked to analyse the 11C-choline uptake for PET/CT scans in four randomized rounds for all 21 patients, with increasing scan duration per round. P-values of

Published
2018

33. Adrenal Tracer Uptake by F-18-FDOPA PET/CT in Patients with Pheochromocytoma and Disease Controls

Author

Noordzij, W., Glaudemans, A., Schaafsma, M., Slart, R., van Beek, A., Kerstens, M., Translational Immunology Groningen (TRIGR), Cardiovascular Centre (CVC), Center for Liver, Digestive and Metabolic Diseases (CLDM), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Published
2018

34. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study

Author

Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., Wessels, F., Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Gastroenterology and Hepatology, AGEM - Re-generation and cancer of the digestive system, Nuclear Medicine, Radiology and Nuclear Medicine, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, CCA - Imaging and biomarkers, Radiotherapy, Oncology, ACS - Diabetes & metabolism, AMS - Restoration & Development, ANS - Brain Imaging, Pathology, and AGEM - Digestive immunity

Subjects
Cancer Research, Esophageal Neoplasms, PREDICTION, SURGERY, medicine.medical_treatment, Esophageal cancer, FREE DNA, Study Protocol, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, Pathologic complete response, PATHOLOGICAL COMPLETE RESPONSE, FDG-PET, medicine.diagnostic_test, Image-guided, Chemoradiotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Primary tumor, Neoadjuvant Therapy, Neoadjuvant chemoradiotherapy, medicine.anatomical_structure, Fine-needle aspiration, Treatment Outcome, Oncology, Positron emission tomography, Esophagectomy, 030220 oncology & carcinogenesis, GASTROESOPHAGEAL CANCER, Adenocarcinoma, 030211 gastroenterology & hepatology, Radiology, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], MRI, medicine.medical_specialty, DCE-MRI, PET-CT, lcsh:RC254-282, 03 medical and health sciences, POSITRON-EMISSION-TOMOGRAPHY, DW-MRI, Preoperative Care, medicine, Genetics, Humans, Esophagus, JUNCTIONAL CANCER, business.industry, PERIOPERATIVE CHEMOTHERAPY, ctDNA, medicine.disease, CIRCULATING TUMOR-CELLS, business, Follow-Up Studies
Abstract

Contains fulltext : 200332.pdf (Publisher’s version ) (Open Access) BACKGROUND: Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET-CT). Accurate response prediction could lead to a patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant treatment in case of non-pCR. METHODS: The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and (18)F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points (before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the model for pCR prediction. Secondary endpoints include progression-free and overall survival. DISCUSSION: If the multimodal PRIDE concept provides high predictive performance for pCR, the results of this study will play an important role in accurate identification of esophageal cancer patients with a pCR to nCRT. These patients might benefit from a patient-tailored approach with omission of surgery in the future. Vice versa, patients with non-pCR might benefit from additional neoadjuvant treatment, or ineffective therapy could be stopped. TRIAL REGISTRATION: The article reports on a health care intervention on human participants and was prospectively registered on March 22, 2018 under ClinicalTrials.gov Identifier: NCT03474341 .

Published
2018

35. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

Author

Montes de Jesus, F. M., primary, Kwee, T. C., additional, Kahle, X. U., additional, Nijland, M., additional, van Meerten, T., additional, Huls, G., additional, Dierckx, R. A. J. O., additional, Rosati, S., additional, Diepstra, A., additional, van der Bij, W., additional, Verschuuren, E. A. M., additional, Glaudemans, A. W. J. M., additional, and Noordzij, W., additional

Published
2019
Full Text
View/download PDF

38. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study

Author

Borggreve, A.S., Mook, S., Verheij, M., Mul, V.E.M., Bergman, J.J., Bartels-Rutten, A., Beek, L.C. Ter, Beets-Tan, R.G., Bennink, R.J., Berge Henegouwen, M.I. van, Brosens, L.A.A, Defize, I.L., Dieren, J.M. van, Dijkstra, H., Hillegersberg, R. van, Hulshof, M.C.C., Laarhoven, H.W.M. van, Lam, M., Lier, A. van, Muijs, C.T., Nagengast, W.B., Nederveen, A.J., Noordzij, W., Plukker, J.T., Rossum, P.S.N. van, Ruurda, J.P., Sandick, J.W. van, Weusten, B., Voncken, F.E., Yakar, D., Meijer, G.J, Borggreve, A.S., Mook, S., Verheij, M., Mul, V.E.M., Bergman, J.J., Bartels-Rutten, A., Beek, L.C. Ter, Beets-Tan, R.G., Bennink, R.J., Berge Henegouwen, M.I. van, Brosens, L.A.A, Defize, I.L., Dieren, J.M. van, Dijkstra, H., Hillegersberg, R. van, Hulshof, M.C.C., Laarhoven, H.W.M. van, Lam, M., Lier, A. van, Muijs, C.T., Nagengast, W.B., Nederveen, A.J., Noordzij, W., Plukker, J.T., Rossum, P.S.N. van, Ruurda, J.P., Sandick, J.W. van, Weusten, B., Voncken, F.E., Yakar, D., and Meijer, G.J

Abstract

Contains fulltext : 200332.pdf (publisher's version ) (Open Access), BACKGROUND: Nearly one third of patients undergoing neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer have a pathologic complete response (pCR) of the primary tumor upon histopathological evaluation of the resection specimen. The primary aim of this study is to develop a model that predicts the probability of pCR to nCRT in esophageal cancer, based on diffusion-weighted magnetic resonance imaging (DW-MRI), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and (18)F-fluorodeoxyglucose positron emission tomography with computed tomography ((18)F-FDG PET-CT). Accurate response prediction could lead to a patient-tailored approach with omission of surgery in the future in case of predicted pCR or additional neoadjuvant treatment in case of non-pCR. METHODS: The PRIDE study is a prospective, single arm, observational multicenter study designed to develop a multimodal prediction model for histopathological response to nCRT for esophageal cancer. A total of 200 patients with locally advanced esophageal cancer - of which at least 130 patients with adenocarcinoma and at least 61 patients with squamous cell carcinoma - scheduled to receive nCRT followed by esophagectomy will be included. The primary modalities to be incorporated in the prediction model are quantitative parameters derived from MRI and (18)F-FDG PET-CT scans, which will be acquired at fixed intervals before, during and after nCRT. Secondary modalities include blood samples for analysis of the presence of circulating tumor DNA (ctDNA) at 3 time-points (before, during and after nCRT), and an endoscopy with (random) bite-on-bite biopsies of the primary tumor site and other suspected lesions in the esophagus as well as an endoscopic ultrasonography (EUS) with fine needle aspiration of suspected lymph nodes after finishing nCRT. The main study endpoint is the performance of the model for pCR prediction. Secondary endpoints include progression-free and overall survival. DISCUSSIO

Published
2018

39. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): A multicenter observational study

Author

Onderzoek Radiotherapie, MS Radiotherapie, Cancer, Pathologie Pathologen staf, Fysica Radiotherapie Research, Divisie Beeld & Oncologie, Researchgr. Nucleaire Geneeskunde, Arts-assistenten Radiotherapie, MS CGO, MS MDL 1, Klinische Fysica RT, Verpleegafdeling Hematologie, Unit D (laboranten rath), Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, MS Radiologie, Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., Wessels, F., Onderzoek Radiotherapie, MS Radiotherapie, Cancer, Pathologie Pathologen staf, Fysica Radiotherapie Research, Divisie Beeld & Oncologie, Researchgr. Nucleaire Geneeskunde, Arts-assistenten Radiotherapie, MS CGO, MS MDL 1, Klinische Fysica RT, Verpleegafdeling Hematologie, Unit D (laboranten rath), Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, MS Radiologie, Borggreve, A. S., Mook, S., Verheij, M., Mul, V. E.M., Bergman, J. J., Bartels-Rutten, A., Ter Beek, L. C., Beets-Tan, R. G.H., Bennink, R. J., Van Berge Henegouwen, M. I., Brosens, L. A.A., Defize, I. L., Van Dieren, J. M., Dijkstra, H., Van Hillegersberg, R., Hulshof, M. C., Van Laarhoven, H. W.M., Lam, M. G.E.H., Van Lier, A. L.H.M.W., Muijs, C. T., Nagengast, W. B., Nederveen, A. J., Noordzij, W., Plukker, J. T.M., Van Rossum, P. S.N., Ruurda, J. P., Van Sandick, J. W., Weusten, B. L.A.M., Voncken, F. E.M., Yakar, D., Meijer, G. J., Aleman, B. M.P., Borra, R. J.H., Van Etten, B., Gisbertz, S. S., Goense, L., Haj Mohammad, N., Hartemink, K. J., Kappert, P., Kats-Ugurlu, G., Kodach, L. L., Korteweg, T., Krishnadath, K. K., Langendijk, J. A., De Leng, W. W.J., Meijer, S. L., Potze, J. H., Stoker, J., Vegt, E., Verkooijen, H. M., Vollenbrock, S. E., and Wessels, F.

Published
2018

41. SPECT-based semi-quantitative assessment of I-123-SAP scintigraphy in patients with amyloidosis

Author

van Rheenen, R. W. J., Hazenberg, B. P. C., Noordzij, W., Dierckx, R. A. J. O., Slart, R. H. J. A., Glaudemans, A. W. J. M., Translational Immunology Groningen (TRIGR), Vascular Ageing Programme (VAP), Molecular Neuroscience and Ageing Research (MOLAR), Cardiovascular Centre (CVC), and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Published
2016

42. A negative sentinel node in melanoma patients; no need to worry?

Author

Faut, M., Wevers, K., Noordzij, W., Jalving, M., Van Ginkel, R., Hoekstra, H., Kruijff, S., Been, L., Van Leeuwen, B., Guided Treatment in Optimal Selected Cancer Patients (GUTS), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), and Targeted Gynaecologic Oncology (TARGON)

Subjects
ulcer, predictive value, proportional hazards model, systemic disease, clinical study, head, university hospital, neck, thickness, sentinel lymph node, risk factor, data base, melanoma, follow up, human, recurrence risk
Abstract

Background: Since its introduction, the outcome of the SLNB is one of the most important prognostic factors in melanoma patients. A negative sentinel node however, does not guarantee a recurrence-free follow-up. This study was performed to determine risk factors of regional or systemic disease recurrence in node negative melanoma patients. Material and methods: Data concerning patients treated between 1996 and 2014 in the University Medical Center Groningen were prospectively collected. The database contained patient and tumor characteristics, follow-up, recurrence and survival data. Cox regression analyses were used to determine variables associated with systemic first site of recurrence in sentinel node negative patients. Results: A total of 668 SLNB's were performed between 1996 and 2014. The SLNB was positive in 27.8% of the patients and negative in 68.6% of the patients. Recurrence rates were 53.2% in the SLNB positive group and 17.9% in the SLNB negative group. Thirty and a half percent of all patients recurred (204/668), 77% of these patients progressed to stage IV during the course of their disease. Multivariate cox regression analysis of factors associated with immediate stage IV recurrence in sentinel node negative patients revealed melanoma located on the head/neck (HR 3.09, p: 0.035) and the presence of ulceration (HR 2.31, p: 0.035) as significant factors. In sentinel node negative patients with a nodular melanoma the ever recurrence rate was 38/128 (29.7%), if ulceration was present the recurrence rate was 43.1%, the first site of recurrence was systemic in 64% of these patients. Analysis of ever stage IV recurrence in all patients revealed SLNB positive results of strong predictive value (HR 3.00, P

Published
2016

43. False positive findings on 6-[18F]fluor-L-3,4-dihydroxyphenylalanine Positron Emission Tomography (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors

Author

Berends, MA, primary, Bolt, JW, additional, Kerstens, MN, additional, Links, TP, additional, Korpershoek, E, additional, de, Krijger RR, additional, Walenkamp, AME, additional, Noordzij, W, additional, van, Etten B, additional, Kats-Urgurlu, G, additional, Brouwers, AH, additional, and van, der Horst-Schrivers ANA, additional

Published
2017
Full Text
View/download PDF

45. Cost-effectiveness of radium-223 compared to best standard of care, abiraterone acetate and enzalutamide in the treatment of castration resistant prostate cancer in the Netherlands

Author

De Meijer, C., Baka, Agni, Leliveld-Kors, A., Noordzij, W., Gaultney, J., and ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE)

Subjects
safety, castration resistant prostate cancer, n [bis(1 aziridinyl)phosphinyl] 4 iodobenzamide, population, health status, prostate specific antigen, European, survival, sensitivity analysis, death, quality adjusted life year, human, Netherlands, progression free survival, model, enzalutamide, cost effectiveness analysis, disease course, medical specialist, health, landscape, health care, radium, abiraterone acetate, health care quality, patient, alkaline phosphatase, neoplasm, lifespan, budget
Abstract

Background: The treatment landscape of metastatic castration resistant prostate cancer (mCRPC) has changed with the introduction of abiraterone acetate (AA), enzalutamide (EN) and radium-223 (Ra-223). Little is known about the cost-effectiveness of these novel agents. This study investigates the cost-effectiveness of Ra-223 in the Netherlands. First, the costeffectiveness of Ra-223 will be evaluated against best supportive care (BSoC) in the mCRPC population. Second, the cost-effectiveness of Ra-223 in the post-chemo setting will be evaluated against the active comparators AA and EN. Material and Methods: A Markov model with five health states is used to describe disease progression and evaluate the cost-effectiveness. The health states are: progression-free survival (PFS) without a symptomatic skeletal event (SSE), progressed disease without SSE, PFS after experiencing a SSE, progressed disease after experiencing a SSE, and death. Disease progression is measured by alkaline phosphatase (comparator=BSoC) or prostate specific antigen. Efficacy, safety and quality adjusted life year (QALY) data were extracted from Phase III RCT's. Efficacy and safety of Ra-223 versus AA and EN was obtained by indirect treatment comparisons. The model has been validated by specialists treating mCRPC. Analyses were performed from a societal perspective, including costs outside the health care budget. Results: Compared to BSoC, Ra-223 has higher quality adjusted survival (0.29 QALYs) and lifetime costs (€22.485) in mCRPC patients, resulting in an incremental cost-effectiveness ratio of €78.642 per QALY. This is below the proposed Dutch threshold of €80.000. Probabilistic sensitivity analyses reveal a 33% chance for Ra-223 to be cost-effective compared to BSoC at this threshold. Cost-effectiveness of Ra-223 in the postchemo setting compared to active comparators is as follows. While quality adjusted survival of Ra-223 is similar to AA, Ra-223 has lower lifetime costs (€5.905), which are mainly driven by lower drug and SSE treatment costs. Probabilistic sensitivity analyses show a 78% chance for Ra-223 to be cost-effective compared to AA at a threshold of €80.000. Compared to EN, Ra-223 has a slightly lower QALY gain (-0.06) and lower lifetime costs (-€7.255), resulting in only a 19% chance of EN to be cost-effective compared to Ra-223 at a €80.000 threshold. Conclusions: Our model suggests that Ra-223 may be cost-effective compared to BSoC and AA in the Netherlands, with Ra-223 even dominating AA (evaluated in post-chemo patients only). Although EN may lead to slightly more health in post-chemo patients, this health gain is accompanied by extra costs resulting in EN not being considered costeffective compared to Ra-223 according to the Dutch threshold. Ra-223's cost-effectiveness compared to AA and EN should be interpreted with caution due to indirect treatment comparisons.

Published
2015

50. Impact of Endoscopic Ultrasonography on F-FDG-PET/CT Upfront Towards Patient Specific Esophageal Cancer Treatment.

Author

Hulshoff, J., Mul, V., Boer, H., Noordzij, W., Korteweg, T., Dullemen, H., Nagengast, W., Oppedijk, V., Pierie, J., and Plukker, John

Abstract

Introduction: In patients with potentially resectable esophageal cancer (EC), the value of endoscopic ultrasonography (EUS) after fluorine-18 labeled fluorodeoxyglucose positron emission tomography with computed tomography (F-FDG-PET/CT) is questionable. Retrospectively, we assessed the impact of EUS after PET/CT on the given treatment in EC patients. Methods: During the period 2009-2015, 318 EC patients were staged as T1-4aN0-3M0 with hybrid F-FDG-PET/CT or F-FDG-PET with CT and EUS if applicable in a nonspecific order. We determined the impact of EUS on the given treatment in 279 patients who also were staged with EUS. EUS had clinical consequences if it changed curability, extent of radiation fields or lymph node resection (AJCC stations 2-5), and when the performed fine-needle aspiration (FNA) provided conclusive information of suspicious lymph node. Results: EUS had an impact in 80 (28.7%) patients; it changed the radiation field in 63 (22.6%), curability in 5 (1.8%), lymphadenectomy in 48 (17.2%), and FNA was additional in 21 (7.5%). In patients treated with nCRT ( n = 194), EUS influenced treatment in 53 (27.3%) patients; in 38 (19.6%) the radiation field changed, in 3 (1.5%) the curability, in 35 (18.0%) the lymphadenectomy, and in 17 (8.8%) FNA was additional. EUS influenced both the extent of radiation field and nodal resection in 31 (16.0%) nCRT patients. Conclusions: EUS had an impact on the given treatment in approximately 29%. In most patients, the magnitude of EUS found expression in the extent of radiotherapy target volume delineation to upper/high mediastinal lymph nodes. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results